BCLI
Brainstorm Cell Therapeutics Inc.0.5800
+0.0300+5.45%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
6.40MP/E (TTM)
-Basic EPS (TTM)
-1.42Dividend Yield
0%Recent Filings
8-K
$1M private placement closed
Brainstorm Cell Therapeutics entered a $1M private placement on February 24, 2026, with an accredited investor, closing $125K initially and up to $875K more by September 25 via eight closings at $0.60/share or pre-funded warrants. Common warrants for 120% of shares issued carry $1.00 exercise price over five years; proceeds fund working capital. Board boosted 2014 plans' shared pool by 5.5M shares to 8.4M. Dilution looms large.
8-K
BCLI closes $1M PIPE
Brainstorm Cell Therapeutics closed a $500,000 first tranche private placement on February 9, 2026, with an accredited investor, issuing common stock or pre-funded warrants at $0.60 each plus common warrants for 120% more shares at $1.00 exercisable five years. Second $500,000 closing follows in 30 days; proceeds fund working capital. Warrants cap ownership at 4.99% or 9.99%. Dilution looms large.
8-K
Issues $329k convertible notes
Brainstorm Cell Therapeutics issued three unsecured convertible promissory notes totaling $329,175 principal to institutional investors on Dec 31, 2025–Jan 6, 2026, netting ~$288,000 after discounts and fees. Notes carry 10-12% one-time interest, mature in 12 months, and convert post-default at 65-75% of recent low prices with 4.99% ownership caps. High-risk financing signals cash strain, but dilutes equity on trigger.
8-K
Issued $144K convertible note
Brainstorm Cell Therapeutics issued a $143,750 promissory note to Labrys Fund II on November 10, 2025, netting $121,500 after fees and OID. Monthly $22,589 payments start May 2026 through maturity November 10, 2026; default triggers conversion at 25% discount to 20-day low, capped at 4.99% ownership. Q3 cash dwindled to $0.23M amid $2.1M net loss, yet Phase 3b ALS trial advances. Dilution looms.
10-Q
Q3 FY2025 results
Brainstorm narrowed its Q3 operating loss to $2.0M from $3.0M y/y, while nine-month loss eased to $7.7M from $8.5M as R&D expenses fell 13.9% to $899K and G&A halved to $1.1M, driven by lower payroll and PR costs. Cash dwindled to $5K amid $1.1M operating burn, offset by $313K ATM proceeds and warrant exercises that doubled shares outstanding to 11M—EPS improved to $(0.19) from $(0.51). Short-term loans outstanding sit at $101K. Nasdaq delisting curbs liquidity.
IPO
Employees
Sector
Industry
ALZN
Alzamend Neuro, Inc.
2.16+0.05
BCTX
BriaCell Therapeutics Corp.
8.70-0.28
BRTX
BioRestorative Therapies, Inc.
1.08-0.03
BSEM
BioStem Technologies, Inc.
3.84-0.11
BTAI
BioXcel Therapeutics, Inc.
1.88+0.01
BZYR
Burzynski Research Institute, I
0.03-0.00
CELU
Celularity Inc.
1.35-0.05
CLDI
Calidi Biotherapeutics, Inc.
1.30-0.03
ISCO
International Stem Cell Corp.
0.14-0.03
NRSN
NeuroSense Therapeutics Ltd.
0.85+0.01